ATE17653T1 - Mit einem antimelanoma-antikoerper verbundene ricin-a-kette enthaltende antikrebs-heilmittel und verfahren zu ihrer herstellung. - Google Patents

Mit einem antimelanoma-antikoerper verbundene ricin-a-kette enthaltende antikrebs-heilmittel und verfahren zu ihrer herstellung.

Info

Publication number
ATE17653T1
ATE17653T1 AT82400651T AT82400651T ATE17653T1 AT E17653 T1 ATE17653 T1 AT E17653T1 AT 82400651 T AT82400651 T AT 82400651T AT 82400651 T AT82400651 T AT 82400651T AT E17653 T1 ATE17653 T1 AT E17653T1
Authority
AT
Austria
Prior art keywords
timelanoma
antibody
preparation
methods
curing agents
Prior art date
Application number
AT82400651T
Other languages
English (en)
Inventor
Franz Klauss Jansen
Pierre Gros
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of ATE17653T1 publication Critical patent/ATE17653T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT82400651T 1981-04-15 1982-04-09 Mit einem antimelanoma-antikoerper verbundene ricin-a-kette enthaltende antikrebs-heilmittel und verfahren zu ihrer herstellung. ATE17653T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8107596A FR2504010B1 (fr) 1981-04-15 1981-04-15 Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
EP82400651A EP0063988B1 (de) 1981-04-15 1982-04-09 Mit einem Antimelanoma-Antikörper verbundene Ricin-A-Kette enthaltende Antikrebs-Heilmittel und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
ATE17653T1 true ATE17653T1 (de) 1986-02-15

Family

ID=9257448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82400651T ATE17653T1 (de) 1981-04-15 1982-04-09 Mit einem antimelanoma-antikoerper verbundene ricin-a-kette enthaltende antikrebs-heilmittel und verfahren zu ihrer herstellung.

Country Status (30)

Country Link
US (1) US4414148A (de)
EP (1) EP0063988B1 (de)
JP (1) JPS57179124A (de)
KR (1) KR880001045B1 (de)
AR (1) AR228394A1 (de)
AT (1) ATE17653T1 (de)
AU (1) AU556641B2 (de)
CA (1) CA1195248A (de)
CZ (1) CZ256482A3 (de)
DD (1) DD204849A5 (de)
DE (1) DE3268752D1 (de)
DK (1) DK159277C (de)
EG (1) EG15718A (de)
ES (1) ES511433A0 (de)
FI (1) FI76693C (de)
FR (1) FR2504010B1 (de)
GR (1) GR69199B (de)
HU (1) HU188314B (de)
IE (1) IE53009B1 (de)
IL (1) IL65441A0 (de)
MA (1) MA19429A1 (de)
NO (1) NO154905C (de)
NZ (1) NZ200302A (de)
OA (1) OA07069A (de)
PH (1) PH20846A (de)
PL (1) PL135800B1 (de)
PT (1) PT74741B (de)
SU (1) SU1329604A3 (de)
YU (1) YU83082A (de)
ZA (1) ZA822528B (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
FR2523445A1 (fr) * 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
WO1983003971A1 (en) * 1982-05-12 1983-11-24 President And Fellows Of Harvard College Hybrid proteins
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
JPS5990052A (ja) * 1982-11-16 1984-05-24 Katsu Taniguchi モノクロ−ナル特異抗体を用いたメラノ−マ診断薬
US4916213A (en) * 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
US4591572A (en) * 1983-04-01 1986-05-27 Sloan-Kettering Institute For Cancer Research Pigmentation associated, differentiation antigen of human melanoma and autologous antibody
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
GB2142428A (en) * 1983-06-23 1985-01-16 Erba Farmitalia Adenocarcinoma related antigenic determinants and antibodies specific thereto
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
FR2570278B1 (fr) * 1984-09-14 1987-02-13 Pasteur Institut Compositions et procede pour proteger les lymphocytes t contre l'agent etiologique des lymphadenopathies et du syndrome d'immunodepression acquise
EP0232447A1 (de) * 1986-02-13 1987-08-19 Xoma Corporation Lektin-Immunotoxine
AU585940B2 (en) * 1984-09-25 1989-06-29 Xoma Corporation Lectin immunotoxins
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
US4851510A (en) * 1984-11-30 1989-07-25 Wadley Technologies, Inc. Monoclonal antibodies to novel melanoma-associated antigens
US5256413A (en) * 1985-01-08 1993-10-26 The General Hospital Corporation Method and use for site-specific activation of substances
AT384549B (de) * 1985-01-08 1987-11-25 Strasser Engelbert Verfahren zur herstellung einer vaccine
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
US4744981A (en) * 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
DE3688137D1 (de) * 1985-11-29 1993-04-29 Consolidated Pharmaceuticals L Ricin-antikoerper-konjugate.
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
US4689401A (en) * 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
USRE38008E1 (en) 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5009995A (en) * 1986-10-27 1991-04-23 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to melanoma cells
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
IE20000918A1 (en) * 1990-03-22 2001-05-30 Sloan Kettering Inst Cancer GP75 As a Tumor Vaccine for Melanoma
NZ237688A (en) * 1990-04-19 1993-01-27 Res Dev Foundation Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment
US5981194A (en) * 1992-07-10 1999-11-09 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
US5690935A (en) * 1995-01-13 1997-11-25 Regents Of The University Of Minnesota Biotherapy of cancer by targeting TP-3/P80
EP0873363B1 (de) 1995-06-14 2010-10-06 The Regents of The University of California Hochaffine humane antikörper gegen tumorantigene
AU741338B2 (en) * 1996-09-20 2001-11-29 Bristol-Myers Squibb Company Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
US6869604B1 (en) * 1998-03-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant anti-tumor RNAse
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
DE69940465D1 (de) * 1998-05-08 2009-04-09 Univ California Verfahren zum nachweis und hemmung der angiogenese
CA2424817A1 (en) 2000-10-06 2002-04-11 Quantum Dot Corporation Cells having a spectral signature, and methods of preparation and use thereof
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
EP2381116A1 (de) 2000-11-16 2011-10-26 California Institute of Technology Vorrichtungen und Verfahren zur Durchführung von Tests und Screening mit hohem Durchsatz
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US6955888B2 (en) * 2001-06-11 2005-10-18 Xenoport Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter
IL159894A0 (en) * 2001-07-17 2004-06-20 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins
CA2467587A1 (en) 2001-11-30 2003-06-12 Fluidigm Corporation Microfluidic device and methods of using same
US20030158089A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Administrative agents via the SMVT transporter
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US20030228619A1 (en) * 2002-06-10 2003-12-11 Xenoport, Inc. Peptide nucleic acids as tags in encoded libraries
CA2488858A1 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
AU2003250658B2 (en) 2002-07-18 2009-07-16 Helix Biopharma Corp. Use of urease for inhibiting cancer cell growth
US20040161424A1 (en) * 2002-10-08 2004-08-19 Xenoport Human organic solute transporters
JP5419248B2 (ja) 2003-04-03 2014-02-19 フルイディグム コーポレイション マイクロ流体装置およびその使用方法
CA2553035A1 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
JP2008503217A (ja) 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド 新規抗原結合ポリペプチド及びそれらの使用
EP1771573A4 (de) 2004-07-21 2009-02-18 Ambrx Inc Nichtnatürliche kodierte aminosäuren verwendende biosynthetische polypeptide
EP1828405A4 (de) * 2004-11-16 2009-04-15 Sienna Cancer Diagnostics Ltd Verfahren zum nachweis eines analyten in einer probe
BRPI0518661A2 (pt) 2004-12-22 2008-12-02 Ambrx Inc mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante
CN102732588B (zh) 2004-12-22 2015-01-07 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
ATE542920T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Modifiziertes menschliches wachstumshormon
SG158186A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US20060171919A1 (en) * 2005-02-01 2006-08-03 Research Development Foundation Targeted polypeptides
EP1861512A4 (de) 2005-03-18 2009-12-09 Fluidigm Corp Wärmereaktionsvorrichtung und verwendungsverfahren dafür
WO2006133089A2 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
MX2008002149A (es) * 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
PT1954710E (pt) * 2005-11-08 2011-06-07 Ambrx Inc Aceleradores para a modificação de aminoácidos nãonaturais e polipeptídeos de aminoácidos não-naturais
CN101454461A (zh) 2005-11-16 2009-06-10 Ambrx公司 包括非天然氨基酸的方法和组合物
CA2882445A1 (en) * 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP2615108B1 (de) * 2006-09-08 2016-10-26 Ambrx, Inc. Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen
US9133495B2 (en) * 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
WO2008030614A2 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
WO2008109852A2 (en) 2007-03-07 2008-09-12 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
WO2008137471A2 (en) * 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EP2192922A4 (de) 2007-09-17 2010-09-29 Univ California Auf prostatazellen in situ abzielende internalisierende humane monoklonale antikörper
JP5591701B2 (ja) 2007-09-21 2014-09-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 強力なアポトーシス活性および抗腫瘍活性を示すターゲティング化インターフェロン
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
IL198123A0 (en) 2008-04-18 2009-12-24 Snecma Propulsion Solide A heat treatment oven with inductive heating
EP2304439A4 (de) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc Anti-phospho-akt-antikörper
NZ600382A (en) * 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
EA201170493A1 (ru) 2008-09-26 2011-10-31 Амбркс, Инк. Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот
HUE035168T2 (en) 2008-09-26 2018-05-02 Ambrx Inc Modified animal erythropoietin polypeptides and their applications
US8889156B2 (en) 2009-02-06 2014-11-18 The Regents Of The University Of California Calcium-binding agents induce hair growth and/or nail growth
EP2805965A1 (de) 2009-12-21 2014-11-26 Ambrx, Inc. Modifizierte Schweine-Somatotropin-Polypeptide und deren Verwendungen
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
SI3572091T1 (sl) 2010-08-17 2024-07-31 Ambrx, Inc., Modificirani polipeptidi relaksina in njihova uporaba
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US9090691B2 (en) 2010-09-15 2015-07-28 Applied Molecular Transport Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
SG10201510366RA (en) 2010-09-29 2016-01-28 Uti Limited Partnership Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US20140170068A1 (en) 2011-03-11 2014-06-19 Board Of Regents Of The University Of Nebraska Biomarker for coronary artery disease
DK2694095T3 (en) 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
MX371526B (es) 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
KR102356286B1 (ko) 2011-05-27 2022-02-08 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
EP2822575B1 (de) 2012-03-03 2020-05-06 ImmunGene, Inc. Manipulierte antikörper-interferon-mutante fusionsmoleküle
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
WO2013185117A1 (en) 2012-06-07 2013-12-12 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
US20150152187A1 (en) 2012-06-14 2015-06-04 Ambrx, Inc. Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides
EP2861262B1 (de) 2012-06-19 2018-11-28 Ambrx, Inc. Anti-cd70-antikörper-arzneimittelkonjugate
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
CN105247047A (zh) 2013-04-08 2016-01-13 赫利克斯生物药品公司 抗体-尿素酶偶联物在诊断和治疗中的应用
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US10519247B2 (en) 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
RU2696876C2 (ru) 2013-11-04 2019-08-07 Ютиай Лимитед Партнершип Способы и композиции для устойчивой иммунотерапии
FR3018526B1 (fr) 2014-03-14 2021-06-11 Herakles Installation de densification cvi comprenant une zone de prechauffage a forte capacite
MX385898B (es) 2014-05-07 2025-03-18 Applied Molecular Transp Llc Moleculas de fusion derivadas de la toxina colix para suministro oral de una carga biologicamente activa.
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
EP3291832B1 (de) 2015-05-06 2025-09-03 UTI Limited Partnership Nanopartikelzusammensetzungen zur verzögerten therapie
US11851488B2 (en) 2015-11-03 2023-12-26 Ambrx, Inc. Anti-CD3-folate conjugates and their uses
FI3383920T3 (fi) 2015-11-30 2024-04-10 Univ California Kasvainspesifinen hyötyaineen antaminen ja immuuniaktivointi käyttämällä erittäin spesifiseen kasvainsolun pinta-antigeeniin kohdentuvaa ihmisen vasta-ainetta
US20190161523A1 (en) 2016-04-12 2019-05-30 Blaze Bioscience, Inc. Methods of treatment using chlorotoxin conjugates
WO2017181149A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
US12049511B2 (en) 2016-11-10 2024-07-30 Fortis Therapeutics, Inc. Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
US11434301B2 (en) 2016-11-11 2022-09-06 The Regents Of The University Of California Anti-CD46 antibodies and methods of use
US20180163270A1 (en) 2016-12-12 2018-06-14 Cepheid Integrated immuno-pcr and nucleic acid analysis in an automated reaction cartridge
WO2018129200A2 (en) 2017-01-05 2018-07-12 The Regents Of The University Of California Pac1 receptor agonists (maxcaps) and uses thereof
BR112019016139A2 (pt) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
CA3083748A1 (en) 2017-11-29 2019-06-06 Uti Limited Partnership Methods of treating autoimmune disease
HUE059330T2 (hu) 2018-03-08 2022-11-28 Applied Molecular Transport Inc Toxinból származó bejuttatási konstrukciók orális beadásra
CA3093386A1 (en) 2018-03-08 2019-09-12 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
NZ767804A (en) 2018-03-29 2025-09-26 Ambrx Inc Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
CA3110647A1 (en) 2018-08-28 2020-03-05 Ambrx, Inc. Anti-cd3 antibody folate bioconjugates and their uses
PL3849614T3 (pl) 2018-09-11 2024-04-22 Ambrx, Inc. Koniugaty polipeptydu interleukiny-2 i ich zastosowania
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
PH12022550330A1 (en) 2019-08-16 2023-02-06 Applied Molecular Transport Inc Compositions, formulations, and interleukin production and purification
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
AU2021233909A1 (en) 2020-03-11 2022-09-29 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
AU2021320333A1 (en) 2020-08-07 2023-03-30 Fortis Therapeutics, Inc. Immunoconjugates targeting CD46 and methods of use thereof
EP4199968A1 (de) 2020-08-20 2023-06-28 Ambrx, Inc. Antikörper-tlr-agonist-konjugate, verfahren und verwendungen davon
MX2023011480A (es) 2021-04-03 2023-12-06 Ambrx Inc Conjugados anticuerpo anti-her2-fármaco y usos de estos.
JP2025535713A (ja) 2022-10-07 2025-10-28 アンブレツクス・インコーポレイテツド 薬物リンカー及びその抗体コンジュゲート
EP4651906A1 (de) 2023-01-16 2025-11-26 Ambrx, Inc. Anti-cd70-antikörper-arzneimittelkonjugate
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
WO2025041055A1 (en) 2023-08-22 2025-02-27 Ambrx, Inc. Anti-psma adc conjugate compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
FR2466252A2 (fr) * 1979-10-03 1981-04-10 Clin Midy Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine

Also Published As

Publication number Publication date
ZA822528B (en) 1983-02-23
IE820815L (en) 1982-10-15
EP0063988B1 (de) 1986-01-29
EP0063988A1 (de) 1982-11-03
KR830009777A (ko) 1983-12-23
FR2504010A1 (fr) 1982-10-22
HU188314B (en) 1986-04-28
ES8303918A1 (es) 1983-02-16
KR880001045B1 (ko) 1988-06-18
DK159277B (da) 1990-09-24
CZ256482A3 (en) 1994-01-19
PL235981A1 (de) 1982-10-25
PT74741A (fr) 1982-05-01
IL65441A0 (en) 1982-07-30
NO821198L (no) 1982-10-18
DE3268752D1 (en) 1986-03-13
AR228394A1 (es) 1983-02-28
YU83082A (en) 1985-03-20
DK159277C (da) 1991-02-18
NO154905B (no) 1986-10-06
NO154905C (no) 1987-01-14
PT74741B (fr) 1983-11-09
AU556641B2 (en) 1986-11-13
DK167482A (da) 1982-10-16
ES511433A0 (es) 1983-02-16
FI76693C (fi) 1988-12-12
IE53009B1 (en) 1988-05-11
FI76693B (fi) 1988-08-31
DD204849A5 (de) 1983-12-14
CA1195248A (en) 1985-10-15
PL135800B1 (en) 1985-12-31
FI821304A0 (fi) 1982-04-14
AU8251082A (en) 1983-04-21
JPS57179124A (en) 1982-11-04
PH20846A (en) 1987-05-08
OA07069A (fr) 1984-01-31
SU1329604A3 (ru) 1987-08-07
EG15718A (en) 1986-09-30
US4414148A (en) 1983-11-08
MA19429A1 (fr) 1982-12-31
NZ200302A (en) 1985-03-20
FR2504010B1 (fr) 1985-10-25
FI821304L (fi) 1982-10-16
GR69199B (de) 1982-05-06

Similar Documents

Publication Publication Date Title
ATE17653T1 (de) Mit einem antimelanoma-antikoerper verbundene ricin-a-kette enthaltende antikrebs-heilmittel und verfahren zu ihrer herstellung.
DE3879748D1 (de) Fett- oder oel-zusammensetzung in pulveriger oder koerniger form und verfahren zu ihrer herstellung.
ATA901883A (de) Polydom, verfahren zu seiner herstellung und immunodiagnostische verfahren
DE3871416D1 (de) Mischvorrichtung und verfahren zu ihrer herstellung.
DE3578019D1 (de) Einrichtung mit veraenderlicher spalte und verfahren zu ihrer herstellung.
DE3788058D1 (de) Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
DE3583721D1 (de) Poroese folien und verfahren zu ihrer herstellung.
ATE27244T1 (de) Poroese ptfe-gegenstaende und verfahren zu ihrer herstellung.
DE3381988D1 (de) Verfahren zur kontinuierlichen durchflussanalyse.
DE3381479D1 (de) Vorrichtung und verfahren zur bestimmung besonderer postgebuehren.
DE3768530D1 (de) Methacrylatharz-zusammensetzung und verfahren zu deren herstellung.
NO157924C (no) Anordning for separering av ikke blandbare fluider med forskjellig densitet.
ATE5761T1 (de) Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung.
NL193146B (nl) Werkwijze voor het bereiden van een deeltjesvormige kleurstofsamenstelling.
DE3485628D1 (de) Kupferartiger katalysator und verfahren zu dessen herstellung.
NL189716B (nl) Diorganopolysiloxanen en werkwijze ter bereiding daarvan.
DE3485202D1 (de) Thermoplastische zusammensetzung und verfahren.
IT1199117B (it) Metodo per saggiare sostanze immuno reattive
DE3382712D1 (de) Durch Pfropfung modifiziertes Copolymer und Verfahren zu dessen Herstellung.
DE3672575D1 (de) Farbige einkomponententoner und verfahren zu ihrer herstellung.
NL189006C (nl) Werkwijze voor het bereiden van een vulcaniseerbare polymeersamenstelling en werkwijze voor bereiden van een vulcanisaat daarvan.
PT72603A (de) Getterkorper und verfahren zu dessen herstellung
DE3875551D1 (de) Verfahren zur bestimmung der teilchengroesse.
ES522186A0 (es) Metodo de ensayo de anticuerpos.
DE3581161D1 (de) Ferrimagnetische teilchen und verfahren zu ihrer herstellung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee